Huons Global휴온스글로벌

Huons Global's shares have fallen about 62% over the past year, while its filings show a merger decision and a disclosure-compliance review that is now deferred.

Huons Global is a holding company whose subsidiaries cover pharmaceuticals, dermatology and aesthetics, medical devices, health foods and drug packaging. Trailing twelve-month revenue to H1 2026 was ₩846.8B, with operating income of ₩68.4B and net income of ₩22.6B, below 2025 levels. The stock closed at ₩22,200, near its 52-week low of ₩20,100 and well below its 52-week high of ₩76,700.

What stands out

• Profitability has weakened: the operating margin fell from 10.7% in 2025 to 8.1% on a trailing basis, and net margin is 2.7%.
• Net income was ₩28.8B in 2025 and ₩22.6B on a trailing basis to H1 2026, after a loss of ₩60.3B in 2022.
• The balance sheet carries ₩292.2B of borrowings against ₩190.2B of cash, with liabilities at 41.4% of equity and free cash flow of ₩56.5B.
• Valuation metrics are low: P/E 12.4, P/B 0.5, dividend yield 4%, market cap ₩281.0B. The company's own DCF model gives a base value of ₩75,025, a bear case of ₩21,544 and a bull case of ₩172,713, a very wide range that is not a forecast.
• Recent filings include a merger decision and a withdrawn in-kind dividend plan, and the company was not designated an unfaithful disclosure company, with the designation deferred. Retail investors sold a net ₩1.1B over the last 20 days, while foreign ownership eased from 7.7% to 7.3%. No news headlines were in the data.

What to watch

• Shareholder meeting and the outcome of the merger proposal, which the filings describe but the data does not detail.
• Whether the deferred unfaithful-disclosure designation is resolved, given that three earlier disclosures were retracted in September.
• The full-year 2026 results, to see if margins recover from 8.1% and whether borrowings stay above cash.